The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 07, 2023
Filed:
May. 02, 2017
Tetragenetics, Inc., Arlington, MA (US);
Paul A. Colussi, Gloucester, MA (US);
Janna Bednenko, Woburn, MA (US);
Yelena Bisharyan, Arlington, MA (US);
Ashot Papoyan, Arlington, MA (US);
Joanna Cardarelli, Charlestown, MA (US);
Theodore G. Clark, Ithaca, NY (US);
Douglas Kahn, Boston, MA (US);
Lore Mariën, Ghent, BE;
Bas Van Der Woning, Bachte-Maria-Leerne, NL;
Hans De Haard, Oudelande, NL;
William D. Harriman, Alameda, CA (US);
Ellen J. Collarini, Oakland, CA (US);
Alka Agrawal, Cambridge, MA (US);
Tetragenetics, Inc., Arlington, MA (US);
Abstract
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.